| | | | | | | | | | | | | | | | | |
| Three Months Ended
September 30, | | Nine Months Ended
September 30, |
| in millions, except per share data | 2024 | 2023 | | 2024 | 2023 |
| | | | | |
| Net sales | $ | 4,209 | | $ | 3,527 | | | $ | 12,186 | | $ | 10,515 | |
| Cost of products sold | 1,312 | | 1,101 | | | 3,791 | | 3,198 | |
| Gross profit | 2,897 | | 2,426 | | | 8,395 | | 7,317 | |
| | | | | |
| Operating expenses: | | | | | |
| Selling, general and administrative expenses | 1,562 | | 1,242 | | | 4,372 | | 3,811 | |
| Research and development expenses | 407 | | 356 | | | 1,156 | | 1,051 | |
| Royalty expense | 5 | | 11 | | | 24 | | 35 | |
| Amortization expense | 205 | | 208 | | | 631 | | 620 | |
| | | | | |
| Intangible asset impairment charges | — | | 1 | | | 276 | | 58 | |
| Contingent consideration net expense (benefit) | (23) | | 12 | | | (4) | | 43 | |
| Restructuring net charges (credits) | 8 | | 15 | | | 12 | | 51 | |
| Litigation-related net charges (credits) | — | | (111) | | | — | | (111) | |
| | | | | |
| 2,164 | | 1,733 | | | 6,467 | | 5,558 | |
| Operating income (loss) | 733 | | 693 | | | 1,928 | | 1,759 | |
| | | | | |
| Other income (expense): | | | | | |
| Interest expense | (79) | | (66) | | | (225) | | (200) | |
| Other, net | 14 | | (18) | | | (7) | | (78) | |
| Income (loss) before income taxes | 669 | | 610 | | | 1,697 | | 1,480 | |
| Income tax expense (benefit) | 200 | | 105 | | | 413 | | 392 | |
| Net income (loss) | 468 | | 504 | | | 1,284 | | 1,088 | |
| Preferred stock dividends | — | | — | | | — | | (23) | |
| Net income (loss) attributable to noncontrolling interests | (0) | | (0) | | | (4) | | (0) | |
| Net income (loss) attributable to Boston Scientific common stockholders | $ | 469 | | $ | 505 | | | $ | 1,288 | | $ | 1,065 | |
| | | | | |
| Net income (loss) per common share - basic | $ | 0.32 | | $ | 0.34 | | | $ | 0.88 | | $ | 0.74 | |
| Net income (loss) per common share - diluted | $ | 0.32 | | $ | 0.34 | | | $ | 0.87 | | $ | 0.73 | |
| | | | | |
| Weighted-average shares outstanding | | | | | |
| Basic | 1,472.7 | | 1,464.5 | | | 1,470.6 | | 1,448.8 | |
| Diluted | 1,487.4 | | 1,475.0 | | | 1,484.5 | | 1,459.1 | |
